

Market Data

Tiziana Life Sciences NASDAQ: TLSA

Fiscal Year	December
Industry	Biotech
Recent Price	\$4.91
Market Cap	\$309M
ADS Outstanding	95.3M
Equity Float	63.1M
Avg. Volume (90-day)	1.3M
Current Assets (mrq)	\$1.5M
Debt (mrq)	\$0.0M

As of Aug. 13, 2020

Company Website
tizianalifesciences.com

Company Overview

Tiziana Life Sciences is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana's two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.

Investment Highlights

- **Transformational platform technologies**
 - Proprietary oral, nasal and inhaled formulation technologies to transform immunotherapies with Monoclonal Antibodies currently administered intravenously
- **Phase 2 oral immunotherapy study for Crohn's Disease (CD)**
 - Phase 2 clinical study with orally administered Foralumab, a fully human anti-CD3 mAb
- **Launching clinical study of COVID-19 monoclonal antibody**
 - Innovative technology enables direct delivery of anti-IL6 receptor monoclonal antibodies into the lung using a handheld inhaler or nebulizer
- **Strong intellectual property protections**
 - 174 foreign patents and 19 U.S. patents issued
- **Planned spinout of genomics-based personalized medicine businesses**
 - StemPrintER is a superior breast cancer prognostic test versus Oncotype DX 40% more accurate in head-to-head study versus Oncotype DX Exact Sciences acquired Oncotype DX for \$2.8 billion
- **Proven leadership team with 'bench to market' experience**
 - Strong entrepreneurial success in biotech deals; CEO: co-founder Synergy Pharma; Executive Chairman founded and chaired two biotechs with \$2B+ market caps Exemplary scientific advisory board with world renowned key opinion leaders



ORAL ADMINISTRATION

Successfully completed Phase 1 trial with orally administered Foralumab

Phase 2 trial in Crohn's Disease to start shortly



NASAL ADMINISTRATION

Phase 1 trial completed for related neurodegenerative diseases such as Progressive Multiple Sclerosis (Pro-MS)

Phase 2 trial in Pro-MS to start shortly.



INHALATION ADMINISTRATION

Preclinical Studies Ongoing

Trial to commence investigating direct delivery of anti-IL6R mAb to the lungs using a portable inhaler

Value Proposition

Tiziana has developed proprietary oral, nasal, and inhaled formulation technologies that could transform immunotherapies with Monoclonal Antibodies currently administered intravenously for multiple indications. Through multiple Phase 2 trials underway and/or planned, the Company is positioned for a steady stream of milestone achievements over the next several quarters. Investors have an additional opportunity for upside value through Tiziana's planned spinout of its genomics-based personalized medicine business, which itself could grow into a multi-billion-dollar operation. Led by a world-class leadership team and scientific advisory board with a collective 76 years of experience in medical technology and more than 100 medical product launches, Tiziana is ideally positioned to execute on its robust corporate strategy.

Pipeline Overview & Upcoming Milestones

Foralumab

Foralumab (TZLS-401) has significant potential as the only fully human engineered anti-human CD3 antibody in clinical development with advantages of short duration of treatment regimen, reduced immunogenicity and prevention of the life-threatening cytokine release syndrome.

- Patent filed on use of Foralumab to enhance success of CAR-T therapy
- Phase 2 trial with orally administered Foralumab in Crohn's Disease patients anticipated completion – Q2 2021
- Phase 2 trial with nasally administered Foralumab in progressive multiple sclerosis (pro-MS) patients anticipated completion – Q2 2021

TZLS-501 (anti-IL6R)

TZLS-501 is a fully human anti IL-6R monoclonal antibody with a novel mechanism of action. The mAb possesses a high affinity for IL-6R and the IL-6/IL-6R complex and effectively blocks the complex even at high IL-6 circulating levels, showing superiority and overcoming the limitations of other IL-6 pathway drugs.

- Development of inhalation technology to deliver stable aerosols directly in lungs – Q2 2021

Milciclib

The Company's lead compound, milciclib, is a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDKs) involved in cell division as well as a number of other protein kinases.

- Initiate Phase 2b in HCC patients with Milciclib in combination with a TKI – Q2 2021

DEVELOPMENT PIPELINE

